Outcomes and Clinical Implications of Intranasal Insulin on Cognition in Humans: A Systematic Review and Meta-analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2023 Jun 28

PMID 37379265

Authors

Sally Wu

Nicolette Stogios

Margaret Hahn

Janani Navagnanavel

Zahra Emami

Araba Chintoh

Philip Gerretsen

Ariel Graff-Guerrero

Tarek K Rajji

Gary Remington

Sri Mahavir Agarwal

Affiliations

Soon will be listed here.

Abstract

Background: Aberrant brain insulin signaling has been posited to lie at the crossroads of several metabolic and cognitive disorders. Intranasal insulin (INI) is a non-invasive approach that allows investigation and modulation of insulin signaling in the brain while limiting peripheral side effects.

Objectives: The objective of this systematic review and meta-analysis is to evaluate the effects of INI on cognition in diverse patient populations and healthy individuals.

Methods: MEDLINE, EMBASE, PsycINFO, and Cochrane CENTRAL were systematically searched from 2000 to July 2021. Eligible studies were randomized controlled trials that studied the effects of INI on cognition. Two independent reviewers determined study eligibility and extracted relevant descriptive and outcome data.

Results: Twenty-nine studies (pooled N = 1,726) in healthy individuals as well as those with Alzheimer's disease (AD)/mild cognitive impairment (MCI), mental health disorders, metabolic disorders, among others, were included in the quantitative meta-analysis. Patients with AD/MCI treated with INI were more likely to show an improvement in global cognition (SMD = 0.22, 95% CI: 0.05-0.38 p = <0.00001, N = 12 studies). Among studies with healthy individuals and other patient populations, no significant effects of INI were found for global cognition.

Conclusions: This review demonstrates that INI may be associated with pro-cognitive benefits for global cognition, specifically for individuals with AD/MCI. Further studies are required to better understand the neurobiological mechanisms and differences in etiology to dissect the intrinsic and extrinsic factors contributing to the treatment response of INI.

Citing Articles

Role of Peripheral and Central Insulin Resistance in Neuropsychiatric Disorders.

Alagiakrishnan K, Halverson T J Clin Med. 2024; 13(21).

PMID: 39518747 PMC: 11547162. DOI: 10.3390/jcm13216607.

Mechanism of traditional Chinese medicine in elderly diabetes mellitus and a systematic review of its clinical application.

Zhang Q, Hu S, Jin Z, Wang S, Zhang B, Zhao L Front Pharmacol. 2024; 15:1339148.

PMID: 38510656 PMC: 10953506. DOI: 10.3389/fphar.2024.1339148.

References

Craft S, Baker L, Montine T, Minoshima S, Watson G, Claxton A . Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2011; 69(1):29-38. PMC: 3260944. DOI: 10.1001/archneurol.2011.233. View

Rosenbloom M, Barclay T, Pyle M, Owens B, Cagan A, Anderson C . A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer's disease. CNS Drugs. 2014; 28(12):1185-9. DOI: 10.1007/s40263-014-0214-y. View

Mustapic M, Tran J, Craft S, Kapogiannis D . Extracellular Vesicle Biomarkers Track Cognitive Changes Following Intranasal Insulin in Alzheimer's Disease. J Alzheimers Dis. 2019; 69(2):489-498. PMC: 6668911. DOI: 10.3233/JAD-180578. View

Hallschmid M, Benedict C, Schultes B, Born J, Kern W . Obese men respond to cognitive but not to catabolic brain insulin signaling. Int J Obes (Lond). 2007; 32(2):275-82. DOI: 10.1038/sj.ijo.0803722. View

Ferrario C, Reagan L . Insulin-mediated synaptic plasticity in the CNS: Anatomical, functional and temporal contexts. Neuropharmacology. 2017; 136(Pt B):182-191. PMC: 5988909. DOI: 10.1016/j.neuropharm.2017.12.001. View

Morris J, Uy R, Vidoni E, Wilkins H, Archer A, Thyfault J . Effect of APOE ε4 Genotype on Metabolic Biomarkers in Aging and Alzheimer's Disease. J Alzheimers Dis. 2017; 58(4):1129-1135. PMC: 5776708. DOI: 10.3233/JAD-170148. View

Agarwal S, Caravaggio F, Costa-Dookhan K, Castellani L, Kowalchuk C, Asgariroozbehani R . Brain insulin action in schizophrenia: Something borrowed and something new. Neuropharmacology. 2019; 163:107633. DOI: 10.1016/j.neuropharm.2019.05.010. View

Higgins J, Altman D, Gotzsche P, Juni P, Moher D, Oxman A . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. PMC: 3196245. DOI: 10.1136/bmj.d5928. View

Kullmann S, Veit R, Peter A, Pohmann R, Scheffler K, Haring H . Dose-Dependent Effects of Intranasal Insulin on Resting-State Brain Activity. J Clin Endocrinol Metab. 2017; 103(1):253-262. DOI: 10.1210/jc.2017-01976. View

10.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

11.

Gwizdala K, Ferguson D, Kovan J, Novak V, Pontifex M . Placebo controlled phase II clinical trial: Safety and efficacy of combining intranasal insulin & acute exercise. Metab Brain Dis. 2021; 36(6):1289-1303. DOI: 10.1007/s11011-021-00727-2. View

12.

Novak V, Mantzoros C, Novak P, McGlinchey R, Dai W, Lioutas V . MemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial. J Neurol. 2022; 269(9):4817-4835. PMC: 9046533. DOI: 10.1007/s00415-022-11119-6. View

13.

Chapman C, Schioth H, Grillo C, Benedict C . Intranasal insulin in Alzheimer's disease: Food for thought. Neuropharmacology. 2017; 136(Pt B):196-201. PMC: 10523803. DOI: 10.1016/j.neuropharm.2017.11.037. View

14.

Reger M, Watson G, Green P, Wilkinson C, Baker L, Cholerton B . Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology. 2007; 70(6):440-8. DOI: 10.1212/01.WNL.0000265401.62434.36. View

15.

Ucer E, Kreger K . A double-blind study comparing haloperidol with thioridazine in emotionally disturbed, mentally retarded children. Curr Ther Res Clin Exp. 1969; 11(5):278-83. View

16.

Novak P, Pimentel Maldonado D, Novak V . Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study. PLoS One. 2019; 14(4):e0214364. PMC: 6483338. DOI: 10.1371/journal.pone.0214364. View

17.

Krug R, Beier L, Lammerhofer M, Hallschmid M . Distinct and Convergent Beneficial Effects of Estrogen and Insulin on Cognitive Function in Healthy Young Men. J Clin Endocrinol Metab. 2021; 107(2):e582-e593. PMC: 8764344. DOI: 10.1210/clinem/dgab689. View

18.

Kellar D, Lockhart S, Aisen P, Raman R, Rissman R, Brewer J . Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer's Disease. J Prev Alzheimers Dis. 2021; 8(3):240-248. PMC: 10233712. DOI: 10.14283/jpad.2021.14. View

19.

Benedict C, Hallschmid M, Schmitz K, Schultes B, Ratter F, Fehm H . Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology. 2006; 32(1):239-43. DOI: 10.1038/sj.npp.1301193. View

20.

Ritze Y, Kern W, Ebner E, Jahn S, Benedict C, Hallschmid M . Metabolic and Cognitive Outcomes of Subchronic Once-Daily Intranasal Insulin Administration in Healthy Men. Front Endocrinol (Lausanne). 2018; 9:663. PMC: 6262365. DOI: 10.3389/fendo.2018.00663. View